Outset Medical (NASDAQ:OM) CEO Leslie Trigg Sells 3,437 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,437 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $4.39, for a total transaction of $15,088.43. Following the completion of the transaction, the chief executive officer owned 194,597 shares of the company’s stock, valued at approximately $854,280.83. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Down 7.3%

OM opened at $4.18 on Wednesday. Outset Medical, Inc. has a 12 month low of $3.00 and a 12 month high of $16.16. The stock has a market cap of $78.58 million, a P/E ratio of -1.02 and a beta of 1.96. The stock’s 50 day moving average price is $4.57 and its 200 day moving average price is $4.23. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The company had revenue of $31.64 million for the quarter, compared to the consensus estimate of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. As a group, research analysts predict that Outset Medical, Inc. will post -3.8 earnings per share for the current year.

Institutional Trading of Outset Medical

A number of institutional investors and hedge funds have recently modified their holdings of OM. Legal & General Group Plc acquired a new position in shares of Outset Medical in the second quarter valued at $34,000. BNP Paribas Financial Markets boosted its position in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Outset Medical by 4.1% in the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock worth $239,000 after acquiring an additional 2,435 shares in the last quarter. Geode Capital Management LLC boosted its stake in Outset Medical by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 400,363 shares of the company’s stock worth $1,486,000 after purchasing an additional 3,104 shares in the last quarter. Finally, Barclays PLC grew its holdings in Outset Medical by 9.8% during the 4th quarter. Barclays PLC now owns 37,682 shares of the company’s stock worth $140,000 after acquiring an additional 3,356 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts have recently issued reports on OM shares. Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Finally, TD Cowen reiterated a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.